Pre-made Abituzumab benchmark antibody ( Whole mAb, anti-ITGAV therapeutic antibody, Anti-CD51/MSK8/VNRA/VTNR Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Abituzumab biosimilar, Whole mAb, Anti-ITGAV Antibody: Anti-CD51/MSK8/VNRA/VTNR therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-003-1mg	1mg	3090
GMP-Bios-ab-003-10mg	10mg	Inquiry
GMP-Bios-ab-003-100mg	100mg	Inquiry
GMP-Bios-ab-003-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Abituzumab biosimilar, Whole mAb, Anti-ITGAV Antibody: Anti-CD51/MSK8/VNRA/VTNR therapeutic antibody
INN Name	Abituzumab
Target	ITGAV
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Merck
Conditions Approved	na
Conditions Active	Colorectal cancer;Systemic scleroderma
Conditions Discontinued	Ovarian cancer;Prostate cancer;Solid tumours
Development Tech	na